Stem cell therapy: what is approved, what is promising, what is oversold

The two studies you should read before you spend anything

In 2025 two separate meta-analyses of randomized controlled trials looked at mesenchymal stem cell injections for knee osteoarthritis. The first, in the Journal of Orthopedic Surgery and Research, pooled the WOMAC scores and found a standardized mean difference of −1.35 at twelve months: a moderate to large treatment effect, and an encouraging result. The second, in Frontiers in Medicine, took eight randomized trials covering 467 patients and asked a harder question: how much of that improvement is the cells, and how much is everything else around them? The answer was that contextual factors accounted for roughly 63 percent of pain reduction at six months, and the authors concluded that the cells themselves confer only a modest incremental benefit.

Both papers are legitimate. Both were published in 2025. A clinic that shows you the first and never mentions the second is not lying to you, but what it is doing is subtler and worse.

What the FDA has actually approved

This is the single most misunderstood fact in the field, and it is easy to check. In the FDA's own words: the only stem cell products that are FDA-approved for use in the United States consist of blood-forming stem cells, also known as hematopoietic progenitor cells, that are derived from umbilical cord blood. Those products are approved for disorders affecting the body's blood-forming system.

Everything else (stem cells for knees, shoulders, backs, fatigue, anti-aging, neurological conditions) is not an FDA-approved treatment. It may be studied under an investigational application, it may be offered under specific regulatory pathways, but it is not approved, and no honest clinic should let you believe otherwise.

Why the dose finding matters more than it sounds

The dose-focused meta-analysis found something commercially inconvenient: lower doses, at or below 25 million cells, were both effective and more efficient, while high doses produced more injection-site pain and swelling without proportionate benefit. In a field where price often scales with cell count, that is worth knowing before someone quotes you for a premium high-dose protocol.

It also tells you that more is not automatically better, which is a useful test to apply to any regenerative offer you receive.

Taking the placebo finding seriously

The instinct is to dismiss placebo effects as "not real". That is wrong. Patients in those trials did feel better. But if most of the benefit comes from context (the consultation, the procedure, the expectation, the attention), then two things follow. First, cheaper and safer interventions may deliver a similar experience. Second, you are entitled to know what proportion of the price is buying biology rather than ceremony.

We would rather have that conversation with you than have you discover it later.

Where the case is strongest

The most consistent human data is in knee osteoarthritis, measured over six to twelve months, in patients with mild to moderate disease. That is a narrow claim, and it is the claim we make. Evidence for shoulders, hips and spine is thinner. Evidence for systemic anti-aging use is essentially absent in humans, whatever the marketing suggests.

If your goal falls outside where the evidence sits, we will say so and point you at what does have evidence for that goal, which is often unglamorous and effective.

Safety, sourcing and the questions to ask

Serious harms from unapproved regenerative products are documented, including infections and injuries from injections into sites the products were never studied for. Sourcing is the thing to interrogate: where did the cells come from, what testing was done, what documentation can the clinic show you, and who is administering them. If a clinic cannot answer those in detail, that is your answer.

Ask also what happens if it does not work: whether there is a defined reassessment point, and what the plan is then. A protocol with no exit is a subscription.

How Organic Well handles regenerative requests

Every regenerative conversation here starts with a medical evaluation, not a price list. We look at whether a better-established option should come first. For a knee that often means load management, strength work, weight and metabolic optimization, and sometimes a referral to orthopedics. If regenerative therapy is still reasonable after that, we discuss the evidence above in full, including the placebo finding, and we set out what we will measure and when we will stop.

Some patients decide to proceed. Some decide not to. We consider both good outcomes of an honest consultation.

The one-line version

Stem cell therapy for knee osteoarthritis has real randomized evidence of benefit at twelve months, a substantial share of which may be contextual, and it is not FDA-approved for that use. If you want to explore it with someone who will hand you both halves of that sentence, book a consultation.